Patient Preferences for use of CAR-T Therapy as an Early Line Treatment in Multiple Myeloma

Doris K. Hansen¹, Jack Khouri², Omar Castaneda Puglianini¹, Yan Zhang³, Kevin De Braganca³, Denise De Wiest³, Matthew Perciavalle⁴, Tamar Lengil³, Stephen Huo³, Seina Lee³, Kathryn Krupsky⁵, Jesse Cohn⁵, Elizabeth Brighton⁵, Todd Bixby³, Zaina P. Qureshi³, Shambavi Richard⁶

H. Lee Moffitt Cancer Center Tampa, FL
 Cleveland Clinic Taussig Cancer Center

- Cleveland, OH
- 3. Janssen Scientific Affairs, LLC, Horsham, PA
- 4. Legend Biotech USA Inc., Somerset, NJ
- 5. Oracle Life Sciences, Austin, TX, USA
- 6. Icahn School of Medicine at Mount Sinai,

Introduction

- MM is genetically complex and heterogeneous; treatment algorithms are well-defined like other neoplasms; MM is an incurable hematological malignancy requiring efficacious therapies for patients to achieve long-term survival¹
 These characteristics of MM create challenges to
 - selecting appropriate regimen sequencing that meet individual patient needs
- Cilta-cel, a BCMA-targeted chimeric antigen receptor T-cell (CAR-T) therapy, has shown depth of response and durability in MM and is approved for patients as early as 2nd line (2L)²
- Data from CARTITUDE-4 showed meaningful clinical and health-related quality of life benefits with the use of cilta-cel

Methods

- A convenience sample of patients from the US were recruited from an online research panel, overseen by SAGO Health,⁶ to participate in a cross-sectional, web-based survey between December 2023-March 2024
- Patients were eligible to complete the survey if they (1) had relapsed or refractory MM, (2) were ≥50 years of age, (3) completed ≥ 1 line of therapy post-MM diagnosis
- To evaluate preferences for CAR-T therapy in earlier lines of MM treatment, a Discrete Choice Experiment (DCE) was included in the survey; patients completed 12 choice tasks where they selected between 2 hypothetical 2L treatment profiles that varied on 7 treatment attributes (Figure 1) to indicate which was preferred
- Choice tasks were hypothetical, though attributes and levels included in the DCE were selected based on targeted literature review, clinical data, expert opinion, and insights gathered from patient focus groups to simulate real clinical decisions

Objectives

To evaluate the influence of key treatment-related attributes on patient preferences for early-line MM therapies



Survival metrics, then safety characteristics around CRS, had the largest impact on patient preferences, suggesting that treatments with the most survival benefit will be preferred by patients; but that shared decision making on early-line treatment should include conversations balancing efficacy and safety characteristics. over current options for patients in earlier lines³

 Aligning treatment decisions with patient preferences contributes to better outcomes for patients;⁴ yet, data are limited on patient preferences for the use of CAR-T, like cilta-cel, in early treatment lines⁵

Results

mOS

Preferences for CAR-T in Early-line Therapy (Figure 1)

- Evidenced by a larger absolute difference between the most and least preferred attribute level, patients' preferences for 2L treatment in MM were most influenced, on average, by:
 - Increasing median OS from 2 additional years to 6 additional years (|-0.88 – 0.81| = 1.69)
 - Increasing median PFS from 7 months to 4 years (|-0.45 0.60| = 1.05)
 - Decreasing the risk of all grade CRS events from 95% to 0% (|-0.54 0.45|) = 0.99
 - Decreasing Serious AEs from 73% to 28% (|-0.29 0.27| = 0.56)
- On average, response rate, dosing / administration, and risk of CAR-Tassociated grade 3/4 neurotoxicity had the least influence on treatment preferences, relative to the other attributes assessed
- While not the most influential factor, patients preferred a one-time infusion over other modes of administration (e.g., weekly or every other day

 Preference weights for attribute levels in the DCE were estimated using Hierarchical Bayesian modeling

Sample Characteristics (Table 1)

- •The survey was administered to 127 patients with MM who reside in the US
- •The mean age was 67 years; most patients were female (54%), White (61%) and on active MM treatment (96%)
- •The majority had received 2 lines of therapy (45%), mean time since MM diagnosis was 71 months, and nearly 10% received CAR-T


Table 1. Patient characteristics

Characteristic		Statistic			
Age (in years; Mean	66.7 ± 4.8				
Gender	Male	54 (42.5%)			
n (%)	Female	69 (54.3%)			
	Other	4 (3.1%)			
Race/Ethnicity	Black or African American	43 (33.9%)			
n (%)	Hispanic / Latino / Latina / Latinx	3 (2.4%)			
	White	78 (61.4%)			
	Other or prefer not to say	4 (3.1%)			
Census Region n (%)	Northeast	25 (19.7%)			
	Midwest	24 (18.9%)			
	South	45 (35.4%)			
	West	33 (26.0%)			
Household Income n (%)	Less than \$100,000 per year	51 (40.2%)			
	\$100,000 to \$124,999	40 (31.5%)			
	\$125,000 or more*	36 (28.3%)			
Months Since Diagn	70.5 ± 82.7				
Age at Diagnosis; M	60.5 ± 8.0				
Currently Undergoin	122 (96.1%)				
Received CAR-T The	12 (9.4%)				
Line of Therapy	1 line	3 (2.4%)			
Received for MM n (%)	2 lines	57 (44.9%)			
	3 lines	46 (36.2%)			
	4+ lines	21 (16.5%)			

(i) Conclusion

Patients' treatment preferences were predominantly influenced by survival metrics in 2L treatment for relapsed myeloma, suggesting a potential preference for CAR-T-like therapies given the demonstrated PFS benefit in as early as 2L+ patients in CARTITUDE-4. However, the safety profiles associated with CAR-T should be clearly communicated, as the associated risks may influence preferences. injection)

Figure 1. Attribute preference weights for treatment characteristics influencing patients' treatment preferences



MM=multiple myeloma

*Includes those who preferred not to say

Acknowledgements

We would like to thank the patients who participated in this study for their time and valuable perspectives.

References

Ve

Funding

This study was sponsored by Johnson & Johnson and Legend Biotech USA Inc.

Disclosures

KD, DD, TL, SH, SL, TB, ZQ, and YZ are paid employees of Johnson & Johnson; MP is employed by and owns stock in Legend Biotech USA Inc.; KK, JC, EB, and RH are employees of Oracle Life Sciences, which provided consulting and research services to Janssen Scientific Affairs for this study.

mPFS	95 out of 100 people have CRS	S6 out of 100 people have CRS	0 out of 100 people have CRS	73 out of 100 peo	50 out of 100 peo	28 out of 100 peo	Neople have n	no O	Cancer respo	Cancer respo	Cancer respo	One-time treatment created by using your l Receive pre-infusion treatment 3 da	Weekly to monthly infusions of drug 1 plus daily t taken by mc	osing	 Combination of 3 drugs: (1) Weekly to monthly days per cycle for 8 cycles; (3) a pill tak
		grade	e)				toxic			rate				inistra	

Abbreviations: AE, adverse event; CRS, cytokine release syndrome; PFS, progression-free survival; OS, overall survival Note: Preference weights should not be interpreted by themselves. Instead, the magnitude of change within one attribute should be compared to change within another attribute; All preference weights of levels within an attribute sum to 0. *CAR-T-associated (grade 3/4) neurotoxicity

Presented by Dr. Doris Hansen at the International Myeloma Society 21st Annual Meeting; Sept. 25-28, 2024; Rio De Janeiro, Brazil

- Manier S, et al. *Nat Rev Clin Oncol*. 2017;14:2:100-113. DOI: 10.1038/nrclinonc.2016.122.
 CARVYKTI[®] (ciltacabtagene autoleucel Prescribing Information. April 2024. Accessed 23 July 2024.
 Janssen Global. 11 December 2023. Accessed 12 September 2024. https://www.janssen.com/treatmentcarvyktir-ciltacabtagene-autoleucel-resulted-clinicallymeaningful-improvements-health.
- 4. Lindhiem O, et al. *Clin Psychol Rev*. 2014;34(6):506-517. DOI: 10.1016/j.cpr.2014.06.002
- 5. Hydren JR, et al. *Front Health Serv*. 2024;4:1354760. DOI: 10.3389/frhs.2024.1354760.
- 6. Sago 2024. https://sago.com/en/company/purpose/.

Multiple Myeloma